Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset

Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes

(2012) J. A. Tennessen et al.   SCIENCE

Improving the Assessment of the Outcome of Nonsynonymous SNVs with a Consensus Deleteriousness Score, Condel

(2011) Abel González-Pérez et al.   AMERICAN JOURNAL OF HUMAN GENETICS

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors

(2011) Steven Lane et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy

(2011) S A Scott et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition

(2011) L. B. Ramsey et al.   GENOME RESEARCH

Genomics and Drug Response

(2011) Liewei Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

The functional spectrum of low-frequency coding variation

(2011) Gabor T Marth et al.   GENOME BIOLOGY

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Single-nucleotide evolutionary constraint scores highlight disease-causing mutations

(2010) Gregory M Cooper et al.   NATURE METHODS

Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment

(2010) Guillaume Paré et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE